CSX Operating Cash Flow decreased by 8.2% to $1.27B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.4%, from $1.26B to $1.27B. Over 4 years (FY 2021 to FY 2025), Operating Cash Flow shows relatively stable performance with a -2.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates strong operational efficiency and cash generation, while a decrease may signal operational challenges or issues with working capital management.
This metric represents the total cash generated or consumed by a company's core business operations during a specific pe...
Standard across all industries; peers in the medical device and diagnostics sector typically maintain high conversion ratios of net income to operating cash flow.
net_cash_from_operating| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.17B | $1.42B | $1.28B | $1.30B | $1.23B | $1.73B | $1.27B | $1.26B | $1.22B | $1.55B | $1.49B | $1.07B | $1.11B | $1.69B | $1.39B | $1.26B | $635.00M | $1.34B | $1.39B | $1.27B |
| QoQ Change | — | +21.7% | -9.9% | +1.5% | -5.2% | +40.1% | -26.3% | -1.2% | -3.1% | +27.5% | -4.1% | -28.4% | +3.8% | +52.3% | -17.7% | -9.6% | -49.4% | +110.6% | +3.7% | -8.2% |
| YoY Change | — | — | — | — | +5.5% | +21.5% | -0.7% | -3.3% | -1.1% | -10.0% | +17.2% | -15.1% | -9.0% | +8.6% | -6.8% | +17.7% | -42.6% | -20.7% | -0.1% | +1.4% |